glp-1 agonists for obesity Comparing Ozempic, Wegovy and Other Drugs Frontiers | GLP−1 receptor agonists
Description
The leaders of tomorrow recognize the complexity of obesity not just as a disease, but as a multifactorial challenge requiring integrated, interdisciplinary solutions
Most people will encounter 10mg/ml or 20mg/ml concentrations
10.1002/trc2.12268 [DOI] [PMC free article] [PubMed] [Google Scholar] Pontes-da-Silva R
Both GLP-1RA and SGLT-2 inhibitors were associated with the same lower risk (12%) as compared with placebo, and the same lower risk as compared with DPP-4 inhibitors (13%)
GLP-1s Results vary
Clin Sci (Lond) (2011) 120(2):7380
